Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges.

The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers. These are investigational candidates and are not approved for commercial use.

Founded in 2018 and based in Carlsbad, California, Tyra conducts drug discovery and clinical development. Todd Harris, a company co-founder, serves as its chief executive officer.

Key Stats

• Today's Range: $20.80 to $22.58
• 50-Day Range: $18.52 to $28.65
• 52-Week Range: $13.83 to $40.65
• Volume: 793,826 shs
• Average Volume: 893,033 shs
• Market Capitalization: $1.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.20
• Consensus Rating: Moderate Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 594th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tyra Biosciences has a consensus price target of $47.20, representing about 124.8% upside from its current price of $21.00.

Amount of Analyst Coverage

Tyra Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.68) to ($2.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.19% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 15.33, which indicates bearish sentiment.

Change versus previous month

Short interest in Tyra Biosciences has recently increased by 0.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Tyra Biosciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $20,004.00 in company stock, which represents 0.0016% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,004.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 11/10/2026
• Last Earnings: 11/10/2026
• Next Earnings (Estimated): 11/10/2026
• Corporate presentation: 11/10/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 87
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Tyra Biosciences: $47.20
• High Price Target: $56.00
• Low Price Target: $29.00
• Potential Upside/Downside: +124.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.39%
• Return on Assets: -43.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.90
• Quick Ratio: 14.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 4.32

Miscellaneous

• Outstanding Shares: 59,680,000
• Free Float: 52,217,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: 0.65